• Cardiovascular Medicine

    Paradigm's CME/CE programs in the cardiology space include those on the topics of Acute Coronary Syndromes, Anticoagulation, Hypertension, Treatment and Prevention of Venous Thromboembolism, and Stroke Prevention in Nonvalvular Atrial Fibrillation.

    To view all our activities about cardiology, thrombosis and other cardiovascular topics, please click here

ADVANCES IN HEART FAILURE PHARMACOTHERAPY

"Advances in Heart Failure Pharmacotherapy" is a 1-hour interactive Webinar developed from a video recording of a live presentation on managing heart failure (HF), an installment of the "Tall Rounds" series of the Cleveland Clinic's Heart and Vascular Institute. An expert multidisciplinary faculty answers a number of crucial management questions in their presentation: How should novel medications be incorporated into the careof HF patients? When should aldosterone receptor antagonists be instituted? When can the combination agent sacubitril/valsartan be considered? What about ivabradine? What are various characteristics of these novel agents - a verse effects, dosage titration, and contraindications? Last, how can multidisciplinary care teams produce better outcomes, as evidenced in part by the Cleveland Clinic experience? These topics are made more immediate and practical through the use of an actual Cleveland Clinic HF case and participant-interactive polling questions.

 

APPLYING GUIDELINE RECOMMENDED AND RECENT EVIDENCE-BASED THERAPIES IN THE TREATMENT OF CHRONIC HEART FAILURE

As the US population ages, more patients are being diagnosed with chronic heart failure (HF). There are established standard-of-care medications, but use of them has been shown to be suboptimal. In the last year, novel therapies have become available, but many clinicians are unclear on their role in the management of chronic HF. In addition, many clinicians want a greater understanding of the underlying pathophysiology of chronic HF. The live symposium and online monograph "Applying Guideline-Recommended and Recent Evidence-Based Therapies in the Treatment of Chronic Heart Failure" will arm cardiologists, primary care providers, hospitalists, emergency medicine specialists, and other clinicians with the information they need to effectively manage chronic HF in a range of patients. The expert faculty will describe the pathophysiology of chronic HF, differentiating between HF with reduced or preserved left ventricular ejection fraction. The faculty will review the most recent updates to evidence-based treatment guidelines, focusing on recommendations for pharmacologic management, and will describe the mechanisms of action of, clinical evidence for, and appropriate use of newer chronic HF therapies.

This activity expires for credit on April 19, 2018

 

DELVING DEEPER INTO THE COMPLEXITIES AND PERPLEXITIES OF ORAL ANTICOAGULATION

You've reached the decision to move away from warfarin and prescribe a novel oral anticoagulant (NOAC) for your patient, to reduce the risk of stroke in nonvalvular atrial fibrillation or to prevent or treat venous thromboembolism. But next steps can be daunting: With which 1 of 4 available NOACs do you individualize therapy? At what dosage? Will age, renal function, or concomitant medications factor into your strategy? And what protocols and agents do you employ when it's necessary to reverse anticoagulation in a patient taking a NOAC who is bleeding or requires surgery? Through challenging case reviews, three experts from Harvard's Brigham and Women's Hospital answer these and other questions about providing safe and efficacious use of NOACs.

This activity expires for credit on January 26, 2018

 

THE EVOLVING ROLE OF ORAL ANTICOAGULATION IN INTERNAL MEDICINE: NVAF, DVT, AND PE BEST PRACTICES

Internal medicine clinicians (IMs) are on the frontlines of managing patients who are eligible for direct oral anticoagulant (DOAC) therapy, including those with nonvalvular atrial fibrillation (NVAF) who are at risk for stroke, and those with venous thromboembolism, including deep vein thrombosis (DVT) and/or pulmonary embolism (PE), who may be at risk for recurrence. This educational initiative, "The Evolving Role of Oral Anticoagulation in Internal Medicine: NVAF, DVT, and PE Best Practices," provides expert-led, evidence-based guidance on the practical, safe, and effective use of DOACs for the optimal treatment of eligible patients in internal medicine. This case-based education will help IMs tailor DOAC use to a variety of clinical scenarios, including special patient populations (eg, elderly or renally impaired patients), while contemplating a broad range of important considerations related to the indications, contraindications, dosing, and pharmacology of the individual agents. It will also address the management of DOACs in the presence of common clinical challenges such as bleeding or the need for surgery.

This activity expires for credit on July 6, 2017

 

UNCOVERING THE NUANCES OF ORAL ANTICOAGULATION FOR OPTIMAL MANAGEMENT OF HOSPITALIZED PATIENTS

During this CME-certified symposium, expert faculty will provide guidance - via didactic lecture and interactive case studies - on how to identify at-risk patients who are candidates for oral anticoagulation therapy in the hospital setting. Through the use of iPad technology to enhance the learning experience, participants will be provided with evidenced-based information allowing for differentiating among the oral anticoagulants, selecting the most appropriate oral anticoagulant for at-risk patients based on individual drug and patient characteristics; and understanding strategies for stopping and reinitiating anticoagulation in patients undergoing surgical procedures.

This activity expired for credit on April 6, 2017

 

NONWARFARIN ORAL ANTICOAGULANTS (NOACS): THE CLINICAL PHARMACIST'S PERSPECTIVE

Few topics are as relevant - or of as intense interest - to contemporary pharmacy practice as the appropriate use of nonwarfarin oral anticoagulants (NOACs) approved by the FDA in January 2015. NOACs offer distinct advantages over warfarin; they have a rapid onset of action, more predictable pharmacologic profiles, and significantly reduced food and drug interactions. This activity offers education for clinical pharmacists on the latest evidence surrounding the different indications for NOACs, proper dosing strategies, management of bleeding, counseling patients on the safe use of NOACs (and how they differ from warfarin), managing and monitoring for food-drug and drug-drug interactions, and managing care transitions.

This activity expired for credit on March 18, 2017

 

CONSIDERATIONS IN THE CLINICAL USE OF NON-WARFARIN ORAL ANTICOAGULATION IN THROMBOSIS

Nonwarfarin oral anticoagulants (NOACs) have emerged as key therapies to prevent and/or treat potentially deadly thrombotic conditions including stroke or systemic embolic events in patients with nonvalvular atrial fibrillation and venous thromboembolism. Although NOACs offer many advantages over conventional therapies, confusion over certain aspects of their safe and effective use in clinical practice persist. This educational activity will provide the latest data and recommendations in a case-based format to help guide the appropriate and confident use of NOACs in a variety of scenarios commonly encountered in clinical practice.

This activity expired for credit on November 9, 2015

 

ANTICOAGULATION IN THE EMERGENCY DEPARTMENT: A CASE-BASED APPROACH TO MANAGING PATIENTS WITH VENOUS THROMBOEMBOLISM AND NONVALVULAR ATRIAL FIBRILLATION

This live, interactive continuing medical education program will review current evidence and strategies for applying the information to confidently make appropriate "real-time" patient-centered treatment decisions in the emergency department with regard to the use of oral anticoagulation, and in particular the nonwarfarin oral anticoagulants. Key information will be presented in the context of patient case scenarios with the opportunity for participants to have their questions addressed by faculty. Topics include red flags for recognition and efficient diagnosis of nonvalvular atrial fibrillation and venous thromboembolism in the emergency department, balanced risk assessment for thrombosis and bleeding, choosing among available oral anticoagulants, and new strategies for managing acute bleeding events.

This activity expired for credit on February 26, 2017

 

CLINICAL PHARMACISTS AND CHRONIC HEART FAILURE: UNDERSTANDING THE ROLE OF NEW AND ESTABLISHED THERAPIES

This initiative will define chronic heart failure (CHF) with reduced ejection fraction (HFrEF or systolic HF) and will provide visual information and expert instruction to help clinical pharmacists differentiate between CHF/HFrEF and CHF with preserved ejection fraction (HFpEF, or diastolic heart failure). Faculty will review existing algorithms for the use of established cardiovascular drugs in treating CHF/HFrEF and describe the mechanisms of action, approved or proposed indications, and role of new and emerging agents in the treatment of CHF/HFrEF. The information presented will be vital to clinical pharmacists who are assuming an ever increasing role on the CHF treatment team.

This activity expired for credit on February 24, 2017

 

KEY UPDATES IN MANAGING ORAL ANTICOAGULATION AND ITS REVERSAL

This series of text- and audio-video-enabled CME/CPE-certified quarterly web newsletters will report on the latest developments in the field of thrombosis management, featuring summaries of important presentations at major medical conferences and embedded interviews with leading clinicians, researchers, and opinion leaders in the field of anticoagulation. These web newsletters will be accessible via the Paradigm website, www.paradigmmc.com, and the Hospital Quality Foundation (HQF) website, www.hospitalqualityfoundation.org and will be distributed quarterly by Paradigm, HQF, and Elsevier.

January 2016 Issue:
This activity expired for credit on January 22, 2017

September 2015 Issue:
This activity expired for credit on September 18, 2016

 

ANTICOAGULATION THERAPY IN PRIMARY CARE: KEEPING YOUR FINGER ON THE PULSE OF CURRENT CLINICAL RECOMMENDATIONS

Atrial fibrillation (AF) is the most common and important cardiac arrhythmia encountered in clinical practice. Even with the availability in recent years of 4 non-warfarin oral anticoagulants (NOACs), many at-risk patients are not assessed or treated appropriately due in part to confusion about where these agents fit in clinical practice. Due to pharmacodynamic and pharmacokinetic differences among the agents, patient-specific risk factors such as renal clearance must be taken into consideration when prescribing an NOAC. This activity has been designed to help primary care clinicians identify at-risk patients with AF, conduct an evidence-based work-up, and develop individualized treatment plans that appropriately utilize newer therapies when indicated.

This activity expired for credit on December 30, 2016

 

OPTIMAL ANTICOAGULATION THERAPY: A PRESCRIPTION FOR IMPROVEMENT

Atrial fibrillation (AF) and venous thromboembolism (VTE) are among the most common and serious thromboembolic conditions seen in clinical practice. Despite the pharmacokinetic and pharmacodynamic advantages of the nonwarfarin oral anticoagulants over warfarin and their similar or better efficacy to reduce the risk of stroke in patients with nonvalvular AF and for recurrent VTE while reducing the risk for serious bleeding, these agents are still not appropriately used. In this CPE initiative, which includes a didactic lecture combined with a clinical case or cases pertinent to the role of the clinical pharmacist as a critical member of the anticoagulation management team, clinical pharmacy-driven strategies to improve processes of care and anticoagulation management (eg, integration of guidelines into clinical practice) are described.

This activity expired for credit in July 2015

 

HOSPITALISTS ON THE FRONTLINE: PREVENTING AND MANAGING THROMBOEMBOLIC EVENTS

This live, interactive CME satellite symposium, presented at Hospital Medicine 2015, included didactic lectures, in-depth moderated Q&A between attendees and faculty, and patient education resources. An enduring web monograph developed from the proceedings features the most clinically relevant content and additional resources such as patient education materials. The interactive CME-certified web monograph is accessible via the Paradigm website, www.paradigmmc.com, the HQF website, and the website for The Hospitalist, www.the-hospitalist.org.

This activity expired for credit on March 31, 2015

 

ACUTE CORONARY SYNDROMES: OPTIMIZING DUAL ORAL ANTIPLATELET THERAPY

This series of CME-certified grand rounds addresses the most current practice guidelines in the management of ACS, and focuses on a better understanding of existing and novel antiplatelet therapy. It was designed for cardiologists, interventional cardiologists, internists, emergency medicine physicians, critical care specialists, hospitalists, as well as residents, fellows, NPs, and PAs who manage patients with ACS.

This activity concluded on January 13, 2014

 

ANSWERING THE CALL: THE ROLE OF HEALTH-SYSTEM PHARMACISTS TO IMPROVE USE OF TARGET-SPECIFIC ORAL ANTICOAGULANTS

This live, interactive CPE symposium presented at ASHP Midyear 2014 included didactic lectures and in-depth moderated Q&A between attendees and faculty, focused on optimal use of target-specific oral anticoagulant. An enduring web monograph developed from the proceedings of the live symposium was hosted on the Paradigm Medical Communications, LLC website (www.paradigmmc.com) and the Power-Pak C.E. website (www.powerpak.com).

This activity expired for credit on March 20, 2016

 

TARGET-SPECIFIC ORAL ANTICOAGULATION: FOCUS ON VENOUS THROMBOEMBOLISM AND ATRIAL FIBRILLATION

This live, interactive CME satellite symposium presented at the American Heart Association (AHA) Scientific Sessions 2014 featured a moderated roundtable discussion among experts in thrombosis management and in-depth, moderated Q&A between attendees and faculty, and focused on optimal use of current and emerging oral anticoagulants for stroke prevention in atrial fibrillation and venous thromboembolism. An enduring CME/CPE on-demand video webinar developed from the proceedings of the live symposium is accessible via the Paradigm website, www.paradigmmc.com, Paradigm's cardiovascular-focused portal, and the myCME website, www.myCME.com.

This activity expired for credit on February 23, 2016

 

TARGETED ORAL ANTICOAGULATION IN THE EMERGENCY DEPARTMENT: KEY FACTORS IN STROKE PREVENTION IN ATRIAL FIBRILLATION

This live, interactive CME satellite symposium presented at ACEP14 included didactic lectures and in-depth moderated Q&A between attendees and faculty, and focused on stroke prevention in atrial fibrillation from an emergency department perspective. An enduring web monograph was developed from the proceedings and was accessible via the Paradigm website, www.paradigmmc.com, as well as via the University of Cincinnati's CME website, www.cme.uc.edu; and the myCME website, www.myCME.com.

This activity expired for credit on January 29, 2016

 

MITIGATING STROKE RISK ACROSS THE CONTINUUM OF CARE: THE ROLE OF TARGETED ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION

This enduring on-demand CME webinar included didactic and case-based discussions presented in a roundtable format and involved experts from the specialties of cardiology, emergency medicine, primary care, and clinical pharmacy. The webinar was hosted on www.paradigmmc.com, and was promoted via several mechanisms, including a robust email campaign to Paradigm's internal database of learners and distribution through PeerAudience's OpenCME Network.

This activity expired for credit on August 11, 2015

 

TARGETED ORAL ANTICOAGULATION: THE HOSPITALIST'S ROLE IN MANAGING STROKE PREVENTION IN ATRIAL FIBRILLATION

This series of live CME symposia was held in alignment with regular meetings of state/regional chapters of the Society of Hospital Medicine. They focused on the pharmacologic differences among the oral anticoagulants, the evidence for restarting anticoagulant therapy following a major bleeding event in patients with nonvalvular atrial fibrillation, and the importance of the transition of care for patients with nonvalvular AF to both the inpatient and outpatient settings.

This activity expired for credit in June 2015

 

MANAGEMENT OF NONVALVULAR ATRIAL FIBRILLATION: MAKING THE DIAGNOSIS, CHOOSING THE APPROPRIATE ORAL ANTICOAGULANT

This series of grand rounds activities focused on developing strategies to screen patients for nonvalvular AF, evaluating the safety and efficacy data for the targeted oral anticoagulants compared with warfarin, and recognizing the cost of stroke and the importance of stroke prevention to patients with nonvalvular AF. Activities included didactic lecture, real-world case study presentations, and a question-and-answer session with the expert faculty presenter.

This activity expired for credit in May 2015

 

CLARIFYING CONCERNS AND CLINICAL CONUNDRUMS: ENSURING APPROPRIATE USE OF TARGET-SPECIFIC ORAL ANTICOAGULANTS

This series of live CPE symposia was held in alignment with meetings of regional-, state-, and local-level chapters of professional pharmacy associations, including the ASHP, the AMCP, and institutional and state pharmacy associations. They focused on validated risk assessment tools to identify patients who may benefit from anticoagulation, selecting the most appropriate agent, and evidence-based strategies to ensure appropriate management of patients on target-specific oral anticoagulants.

This activity expired for credit in March 2015

 

THE EVOLVING ROLE OF BETA BLOCKERS IN THE MANAGEMENT OF HYPERTENSION: EXPERT PERSPECTIVES

This CME-certified, enduring on-demand webinar was comprised of short didactic presentations and an extended roundtable discussion among presenters. The webinar, hosted by Paradigm, was promoted via several mechanisms, including a robust email campaign to Paradigm's growing internal database of learners, and distributed through PeerAudience's OpenCME Network.

This activity expired for credit on January 30, 2015

 

DUAL ORAL ANTIPLATELET THERAPY FOR ACS: IMPROVING STANDARDS OF CARE TO OPTIMIZE OUTCOMES

This live CME-certified symposium at the AHA Scientific Sessions 2014 was designed for cardiologists and interventional cardiologists, primary care physicians, hospitalists, fellows, PAs, NPs, and other healthcare providers caring for patients with ACS. It reviewed the latest guidelines for dual oral antiplatelet therapy for patients presenting with ACS and described recent data on these therapies in patients with UA/NSTEMI and STEMI.

Based on the live presentation, the CME/CE-certified enduring webinar is intended for cardiologists, interventional cardiologists, emergency department physicians, primary care physicians, hospitalists, fellows, PAs, NPs, and other healthcare professionals caring for or interested in the management of patients with ACS.

This activity concluded on July 1, 2014

 

SELECTING DUAL ORAL ANTIPLATELET THERAPY FOR PATIENTS WITH ACUTE CORONARY SYNDROME

This series of live, CME-certified in-hospital grand rounds described contemporary dual antiplatelet therapy guideline recommendations or patients with ACS undergoing intervention, explained data on these therapies in patients with ACS and diabetes and with STEMI. It was designed to educate hospital-based physicians specialists in cardiology, internal medicine, emergency medicine, critical care, hospital medicine, and residents and fellows who manage patients with ACS.

This activity expired for credit on June 13, 2014

 

STROKE PREVENTION IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: INDIVIDUALIZED, PATIENT-FOCUSED TREATMENT

These series of grand rounds activities included didactic lecture, real-world case study presentations, and a brief question-and-answer session with the expert faculty presenter.

This activity expired for credit in December 2014

 

REASSESSING THE ROLE OF β-BLOCKERS IN THE MANAGEMENT OF HYPERTENSION

This live, interactive CME-certified satellite symposium presented at the ACP's Internal Medicine 2014 included didactic lectures, challenging real-world clinical cases, and a question-and-answer session with the faculty panel. The interactive CME/CE-certified enduring web monograph was hosted on the Paradigm website, www.paradigmmc.com, and distributed via several mechanisms, including an aggressive, multifaceted promotional campaign to physicians and healthcare professionals in Paradigm's learner database and PeerAudience's OpenCME Network.

This activity expired for credit on April 8, 2014

 

FRESH FROZEN PLASMA: CURRENT PRACTICES AND ALTERNATIVES

These CME-certified grand rounds activities targeted hospital-based HCPs, blood-bank directors, intensivists, critical care specialists, surgeons (ie, neurological, transplant, trauma, cardiovascular, general), clinical pathologists, emergency department physicians, cardiologists, pharmacy directors, and other HCPs involved in the decision to use blood products. Activities were designed to increase healthcare professionals' understanding of current uses of fresh frozen plasma and the associated safety and efficacy concerns while improving their awareness of newer plasma derivatives and their uses.

This activity expired for credit on April 29, 2013

 

RACE AGAINST THE CLOCK: OVERCOMING CHALLENGES IN THE MANAGEMENT OF ANTICOAGULANT-ASSOCIATED INTRACEREBRAL HEMORRHAGE

This audience-interactive CME satellite symposium was presented at the 81st Neurological Surgeons (AANS) Annual Scientific Meeting, April 27-May 1, 2013. An enduring peer-reviewed publication featured highlights of the live meeting and was distributed as a ride-along supplement in the Journal of Neurosurgery. The digital publication was located on the Paradigm website, www.paradigmmc.com.

This activity expired for credit on July 31, 2015

 

CAPS: CREATING ANTICOAGULATION PLANS TO PREVENT STROKE IN PATIENTS WITH ATRIAL FIBRILLATION

This series of CME/CNE/CPE-certified in-hospital grand rounds included didactic lecture, real-world case study presentations, and a brief question-and-answer session with the expert faculty presenter.

This activity expired for credit in January 2014